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A B S T R A C T
Purpose
To compare tumor characteristics and risk factors of interval breast cancers and screen-detected
breast cancers, taking mammographic density into account.
Patients and Methods
Women diagnosed with invasive breast cancer from 2001 to 2008 in Stockholm, Sweden, with
data on tumor characteristics (n  4,091), risk factors, and mammographic density (n  1,957)
were included. Logistic regression was used to compare interval breast cancers with screen-
detected breast cancers, overall and by highest and lowest quartiles of percent mammo-
graphic density.
Results
Compared with screen-detected breast cancers, interval breast cancers in nondense breasts
( 20% mammographic density) were significantly more likely to exhibit lymph node involvement
(odds ratio [OR], 3.55; 95% CI, 1.74 to 7.13) and to be estrogen receptor negative (OR, 4.05; 95%
CI, 2.24 to 7.25), human epidermal growth factor receptor 2 positive (OR, 5.17; 95% CI, 1.64 to
17.01), progesterone receptor negative (OR, 2.63; 95% CI, 1.58 to 4.38), and triple negative (OR,
5.33; 95% CI, 1.21 to 22.46). In contrast, interval breast cancers in dense breasts ( 40.9%
mammographic density) were less aggressive than interval breast cancers in nondense breasts
(overall difference, P  .008) and were phenotypically more similar to screen-detected breast
cancers. Risk factors differentially associated with interval breast cancer relative to screen-
detected breast cancer after adjusting for age and mammographic density were family history of
breast cancer (OR, 1.32; 95% CI, 1.02 to 1.70), current use of hormone replacement therapy (HRT;
OR, 1.84; 95% CI, 1.38 to 2.44), and body mass index more than 25 kg/m2 (OR, 0.49; 95% CI, 0.29
to 0.82).
Conclusion
Interval breast cancers in women with low mammographic density have the most aggressive
phenotype. The effect of HRT on interval breast cancer risk is not fully explained by
mammographic density. Family history is associated with interval breast cancers, possibly
indicating disparate genetic background of screen-detected breast cancers and interval breast
cancers.
J Clin Oncol 33:1030-1037. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Interval breast cancers are cancers diagnosed in the
interval between two mammographic screening vis-
its. They are either true interval cancers (not present
at screen examination) or false negatives from
screening, with the latter being partly a consequence
of high breast density masking a tumor on the x-ray.
It is known that interval breast cancers have a
more aggressive phenotype compared with screen-
detected cancers, with higher histologic grade, larger
tumor size, higher TNM stage, more estrogen recep-
tor (ER)/progesterone receptor (PR) negativity,1-6
higher proliferation rates,2,3,5-8 and more often a
triple-negative phenotype,2,9 highlighting the im-
portance of identifying women at risk. Apart from
high breast density and hormone replacement
therapy (HRT) use, risk factors for interval breast
cancer are not well established. Studies compar-
ing family history between interval breast cancers
and screen-detected breast cancers have been
inconclusive.2,3,7,8,10-13 Current HRT use has con-
sistently been shown to be more common in interval
breast cancers,1-3,7,10 but whether this is explained
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by masking through increased mammographic density is not known.
There is also little knowledge about associations between interval
breast cancers and reproductive breast cancer risk factors.
We have previously found that interval breast cancers in women
with low, but not high, breast density have worse prognosis compared
with screen-detected breast cancers.14 This suggests an importance of
taking mammographic density into account when studying interval
breast cancers. To our knowledge, no one has yet investigated whether
tumor characteristics and risk factors of interval breast cancers differ
by mammographic density when compared with screen-detected
breast cancers. We compared established familial, reproductive, and
hormonal breast cancer risk factors, as well as tumor characteristics,
between screen-detected breast cancers and interval breast cancers in a
large cohort of screening program participants, assessing associations
in women with high and low mammographic density separately.
PATIENTS AND METHODS
Study approval was granted by the Regional Ethical Review Board in Stock-
holm, Sweden (Karolinska Institutet, DNR2009/254-31/4).
Setting
Phenotypic characterization was performed in the entire population of
women diagnosed with screen-detected breast cancer and interval breast can-
cer from 2001 to 2008 in Stockholm, Sweden. Detailed questionnaire informa-
tion and mammographic images were available for participants in the Libro-1
study nested in the aforementioned population.
Participant Recruitment and Data Collection
All women diagnosed with invasive breast cancer in Stockholm from
2001 to 2008 were identified through the Stockholm-Gotland Regional Breast
Cancer quality register. Women who had been eligible for participation in the
population-based screening program within the last 24 months of diagnosis
(age 40 to 71 years at diagnosis, n  7669) were all assessed for screening
history. Dates of mammographic screening visits and information about the
outcome of each visit were obtained through merges to the mammography
screening database kept at the Stockholm-Gotland Regional Cancer Center.
The database contains attendance and outcome of all visits undertaken within
the population-based mammography screening program for Stockholm
County. All Stockholm women age 50 to 69 have been invited to be screened at
24-month intervals since 1989, whereas women age 40 to 49 were included
from mid-2005 and screened at 18-month intervals. Participation rate was
70%, recall rate was 3%, and detection rate was 0.5% for the study period.15
Full details of the organizational and quality aspects of the Stockholm mam-
mography screening program are described the publication by Lind et al.15
Screen-detected breast cancer was defined as a breast cancer diagnosis made
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Fig 1. Flow chart of study creation,
describing the initial cohort available for
analysis, exclusions made, and final num-
bers of women with phenotype informa-
tion (N  4,091) and image and risk factor




























Fig 2. The distribution of interval cancer diagnoses in the population per each
month of a 24-month screening interval, overall and by lowest and highest
quartile of mammographic density. Expressed as proportion diagnosed per
month (number of interval cancers diagnosed within each 30.5-day interval
divided by the total number of interval cancers).
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after a positive screen finding but before the next visit or end of a normal
screening interval. Interval breast cancer was defined as a breast cancer diag-
nosis made after a negative screen but before the next visit or end of a normal
screening interval. After excluding women diagnosed without a prior screen-
ing visit (n  2,504), women diagnosed after a normal screening interval had
passed (n  928), and 146 women with uncertain mode of detection, 4,091
women with invasive screen-detected breast cancer or interval breast cancer
were identified within the study period (Fig 1).
Tumor characteristics were obtained from merges to the Stockholm-
Gotland Regional Breast Cancer quality register. Lymph node involvement
was dichotomized into positive or negative. Tumor size was categorized as less
than 20 mm, 20 to 40 mm, or more than 40 mm. ER and PR status were
determined using radioimmunoassay or immunohistochemistry (IHC) with
cutoff values of more than 10% positive cells for IHC and more than 0 fmol/g
DNA for radioimmunoassay assays. The information was recorded as negative
or positive in the register according to local laboratories and existing treatment
program. Human epidermal growth factor receptor 2 (HER2) status, assessed
by IHC/immunocytochemistry and confirmed by fluorescence in situ hybrid-
ization analysis if protein levels from IHC/immunocytochemistry showed 2
or 3, was also recorded in the register as positive or negative. Triple-negative
breast cancer was categorized based on ER, PR, and HER2 status. Information
was essentially complete for tumor size and lymph node status, with less than
2% of patients with missing data, whereas more patients were missing data for
ER and PR status (20%). HER2 status was included in the register from 2007
onward, with 13% of patients missing data on HER2 status. Grade was in-
cluded from 2004, with 7% of patients missing data.
Detailed information on risk factors was available for women who were
alive in 2009 and consented to participate in the Libro-1 study. Libro-1 was
established by inviting all women in Stockholm with breast cancer who were
younger than age 80 years at diagnosis and diagnosed between 2001 and 2008,
as identified through Stockholm-Gotland Regional Breast Cancer quality reg-
ister, to participate. Invitations were mailed out in 2009, together with in-
formed consent documents and a link to an online questionnaire. Overall
response rate was 62% (n  5,715). For this study, only invasive interval breast
cancers and screen-detected breast cancers were considered (n  2,507; Fig 1).
HRT use was classified as current, past, or never; current use was defined
as having used HRT pills during year of diagnosis. Pill HRT users who went off
HRT before the year of diagnosis or users of patches or injections at any time
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POR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Tumor size, mm
 20 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
20-40 2.20 1.89 to 2.57 1.96 1.16 to 3.27 1.53 1.03 to 2.29 .46 2.01 1.61 to 2.50 2.32 1.95 to 2.78 .25
 40 2.57 1.93 to 3.43 4.90 1.85–13.05 1.96 0.77 to 5.07 .79 2.24 1.48 to 3.41 2.77 2.00 to 3.85 .36
Lymph nodes
Negative 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Positive 2.38 1.91 to 2.97 3.55 1.74 to 7.13 1.21 0.61 to 2.40 .03 2.25 1.65 to 3 to 08 2.46 1.91 to 3.15 .62
Grade†
1 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
2 1.69 1.33 to 2.16 1.40 0.59 to 3.68 1.06 0.59 to 1.93 .61 1.52 1.05 to 2.22 1.78 1.33 to 2.40 .49
3 3.53 2.72 to 4.61 3.43 1.44 to 9.16 1.90 0.95 to 3.85 .31 3.48 2.36 to 5 to 15 3.56 2.60 to 4.88 .92
Estrogen receptor
Positive 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Negative 2.87 2.32 to 3.54 4.05 2.24 to 7.25 2.06 1.11 to 3.82 .11 2.85 2.13 to 3.83 2.87 2.26 to 3.66 .97
Progesterone receptor
Positive 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Negative 2.07 1.76 to 2.43 2.63 1.58 to 4.38 1.59 0.99 to 2.53 .15 2.27 1.79 to 2.88 1.96 1.62 to 2.37 .29
HER2†
Positive 2.35 1.57 to 3.52 5.17 1.64 to 16.01 0.74 0.15 to 2.75 .03 2.46 1.40 to 4.32 2.29 1.44 to 3.65 .83
Negative 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Triple negative†
Yes 4.22 2.61 to 6.92 5.33 1.21 to 22.46 1.40 0.34 to 5.27 .12 4.72 2.52 to 8.84 3.94 2.28 to 6.83 .59
No 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Histology
Ductal 1.00 Ref 1.00 Ref 1.00 Ref .39 1.00 Ref 1.00 Ref
Lobular 1.16 0.96 to 1.41 0.96 0.45 to 1.88 1.58 0.94 to 2.64 1.40 1.06 to 1.85 1.04 0.82 to 1.31 .17
Overall difference in estimate‡ .004 .06
Overall difference,‡ excluding
histology .008 .11
Abbreviations: HER2, human epidermal growth factor receptor 2; OR, odds ratio; Ref, reference.
Wald test of standardized differences in ORs between groups.
†HER2 was only recorded from 2007. Grade was recorded from 2004.
‡Wald test of sum of standardized differences in ORs between groups.
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point were coded as past users. Women who had never used pills, patches, or
injections, but may have used local HRT at any time, were coded as never users.
Family history of breast cancer was defined as having a mother or sister with
disease and was analyzed as a binary variable (yes or no). BRCA1/2 mutation
status was self-reported (yes or no, where no could mean not tested or tested
negative). Parity was classified as none, one to two children, or three or more
children. Age at menarche was categorized as  or greater than 13 years old.
Oral contraceptive use was categorized as never or ever. Body mass index
(BMI) was calculated from self-reported weight and height at time of ques-
tionnaire and categorized as low ( 20 kg/m2), normal (20 to 25 kg/m2), and
overweight ( 25 kg/m2). Percentages of missing data were 0% to 5% for all
questionnaire variables, except for BRCA (10%) and family history (8%).
Analog mammographic images were collected from radiology depart-
ments and digitized with an Array 2905HD Laser Film Digitizer (Array Corp,
Tokyo, Japan). Mammographic density was measured with the area-based
measure previously described by Li et al.16 Briefly, an algorithm is taught to
distinguish dense area from nondense area by training on image segmentation
data measured by an experienced Cumulus17 analyst, thus mimicking Cumu-
lus. Percent mammographic density was assessed in prediagnostic mediolat-
eral oblique view images of the cancer-free breast and categorized into
quartiles, with cutoffs at 20%, 29.5%, and 40.9% in this population. Women
with contralateral breast cancer arising within 3 months of diagnosis were not
assessed for density (n  163). An image matching our criteria was found for
1,957 (78%) of 2,507 individuals with questionnaire data.
Statistical Analysis
Binary logistic regression analysis was used to study tumor characteristics
of interval breast cancers in the full population of patients with invasive
screen-detected breast cancers or interval breast cancers (N  4,091). We
performed binary logistic regression analyses of interval breast cancers versus
screen-detected breast cancers within separate strata of the highest and lowest
mammographic density quartiles. Differences between estimates from each
stratum were assessed for each exposure using the Wald test. We also
assessed differences by the overall pattern, combining estimates for tumor
size, lymph spread, ER status, PR status, HER2 status, triple-negative
phenotype, grade, and histology into one score. The overall differences
score was obtained by calculating the observed sum of standardized differ-
ences (sum of z statistics) for log-odds ratios (ORs) of low and high
mammographic density and comparing it with the null distribution using
a Wald test. The null distribution was generated from 1,000 simulated data
sets scrambling the outcome variable to obtain null associations. As a
secondary analysis, histology was omitted from the score to assess overall
pattern of differences solely for factors related to prognosis.
Interval breast cancers diagnosed in the first or second year of the
2-year interval were compared separately with screen-detected breast can-
cers using multinomial logistic regression with screen-detected breast can-
cers as the reference group (population-based study; full population, N 
4,091). Differences between estimates for year 1 and year 2 interval breast
cancers were assessed both separately for each exposure, using the Wald
test, and overall, using the same approach of testing observed versus
expected overall z statistics as described earlier for density. Sensitivity
analysis was performed to assess main findings for tumor characteristics in
the subgroup of women with questionnaire information.
Analysis of risk factors for interval breast cancer was performed in the
cohort of women with density information (n  1,957), using binary logistic
regression. All explanatory variables were first tested separately in crude and
age-adjusted models. Variables significantly associated with interval breast
cancer after adjusting for age (P  .05) were tested in multivariable models. To
address the impact of mammographic density on estimates, logistic regression
was performed in strata of the highest and lowest mammographic density
quartiles. Sensitivity analysis including women with missing density informa-
tion was done. To assess potential survivorship bias among women who
provided risk factor information, sensitivity analysis restricted to women di-
agnosed from 2004 to 2008 was performed. Data management was performed
using SAS version 9.4 statistical software (SAS Institute, Cary, NC). Statistical
analysis was performed in SAS version 9.4 and R version 3.1.0 (www.r-
project.org.18 All statistical tests were two-sided, with a cutoff at   .05.
RESULTS
We identified 4,091 women diagnosed with invasive breast cancer
either through mammography screening or during a screening inter-
val (Fig 1). Of the 4,091 cancers, 70% (n  2,844) were screen-
detected breast cancers and 30% (n  1,247) were interval breast
cancers. Of the interval breast cancers, 63% (n  791) were diagnosed
in the second year after a mammography screen, with no apparent
difference in year-wise distribution between dense and nondense
breasts (Fig 2).
Overall, interval breast cancers had worse phenotype compared
with screen-detected breast cancers, as measured by ORs (Table 1).
Women with questionnaire information were no different from the
full cohort (Appendix Table A1, online only). When comparing inter-
val breast cancers according to time since last screen, interval breast
Table 2. Risk Factors in Patients With Interval and Screen-Detected Breast










Age at diagnosis, years
Mean 59.2 59.8
SD 6.1 5.7
40-49 20 3.5 28 2
50-59 284 49.2 576 41.7






 20.5% 100 17.3 389 28.2
20.5%-29.4% 119 20.6 368 26.7
29.5%-40.9% 161 27.9 330 23.9
 40.9% 197 34.1 293 21.2
HRT use
Never 196 35.6 573 43.8
Past 219 29.8 540 41.3





 20 29 5.2 44 3.3
20-25 331 58.8 620 46.6
 25 203 36.6 667 50.1
Missing 14 49
Family history of cancer in
mother or sister
No 423 78.5 1037 82.1
Yes 116 21.5 226 17.9
Missing 38 117
Abbreviations: BMI, body mass index; HRT, hormone replacement therapy;
SD, standard deviation.
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cancers detected within a year of a negative screen were not more
aggressive than those detected after 13 to 24 months (overall differ-
ences, Wald test P  .06; excluding histology, P  .11). In contrast,
analysis by strata of high and low mammographic density showed
differences. Interval breast cancer in the low mammographic density
stratum had the worst phenotype, with higher frequencies of grade 3
disease (OR, 3.43; 95% CI, 1.44 to 9.16), ER-negative status (OR, 4.05;
95% CI, 2.24 to 7.25), PR-negative status (OR, 2.63; 95% CI, 1.58 to
4.38), HER2-positive status (OR, 5.17; 95% CI, 1.64 to 16.01), triple-
negative status (OR, 5.33; 95% CI, 1.21 to 22.46), tumor size more
than 40 mm (OR, 4.90; 95% CI, 1.85 to 13.05), and lymph node
involvement (OR, 3.55; 95% CI, 1.74 to 7.13) compared with screen-
detected breast cancers. For women with dense breasts, there was no
detectable difference between screen-detected breast cancers and in-
terval breast cancers except for tumor size and ER status (Table 1).
Significant interactions between mammographic density and pheno-
type were found for lymph node involvement and HER2 status. The
overall phenotype of interval breast cancers relative to screen-detected
breast cancer was significantly more aggressive among the nondense
breasts (Wald test for overall differences, P  .004; excluding histol-
ogy, P  .008).
The distribution of general breast cancer risk factors significantly
associated with interval breast cancer is shown in Table 2. ORs from
the crude and age-adjusted analysis of general breast cancer risk fac-
tors are listed in Table 3. Current HRT use, high mammographic
density, low BMI, and family history of breast cancer were more
common in patients with interval breast cancers. None of the repro-
ductive risk factors under study or BRCA mutation status was found to
be significantly different between groups, although the point estimates
indicated higher risk among BRCA mutation carriers (Table 3). In
multivariable analysis (Table 4), the OR for family history was 1.32
(95% CI, 1.02 to 1.70), after adjusting for age and mammographic
density. The point estimate was higher among nondense breasts than
dense breasts. The effect of current HRT use persisted after
Table 3. Risk Factors for Interval Breast Cancer
Factor
Crude Model: Interval v Screen-Detected
Breast Cancer
Age-Adjusted Model: Interval v Screen-Detected
Breast Cancer
OR 95% CI P for Trend OR 95% CI P for Trend
Age at diagnosis, years  .001
 50 1.00
50-59 0.69 0.38 to 1.25
 60 0.49 0.27 to 0.89
Mammographic density  .001  .001
 20% 1.00 1.00
20%-29.4% 1.26 0.93 to 1.70 1.28 0.90 to 1.81
29.5%-40.9% 1.90 1.42 to 2.54 1.84 1.31 to 2.57
 40.9% 2.62 1.97 to 3.48 2.89 2.09 to 4.00
Age at menarche, years
 13 1.00 1.00
 13 1.11 0.89 to 1.38 1.13 0.92 to 1.39
Age at first birth, years .19 .24
 20 1.00 1.00
20-25 1.31 0.90 to 1.90 1.34 0.92 to 1.94
 25 1.35 0.93 to 1.96 1.34 0.92 to 1.95
Parity, No. of children .35 .49
0 1.00 1.00
1-2 0.89 0.68 to 1.18 0.91 0.69 to 1.20
 3 0.85 0.61 to 1.28 0.89 0.64 to 1.32
Oral contraceptive usage
Never 1.00 1.00
Ever 1.19 0.93 to 1.51 1.12 0.88 to 1.43
Hormone replacement therapy  .001  .001
Never 1.00 1.00
Past 1.18 0.95 to 1.49 1.32 1.04 to 1.66
Current 2.04 1.55 to 2.67 2.18 1.65 to 2.87
Body mass index, kg/m2  .001  .001
 20 1.00 1.00
20-25 0.81 0.50 to 1.32 0.79 0.49 to 1.30
 25 0.46 0.28 to 0.76 0.47 0.28 to 0.75
Family history (mother or sister)
No 1.00 1.00
Yes 1.26 0.98 to 1.62 1.29 1.01 to 1.67
BRCA1/2 mutation
No 1.00 1.00
Yes 2.37 0.88 to 6.34 2.17 0.80 to 5.89
Family history is defined as having a mother and/or sister(s) with breast cancer.
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adjustments for mammographic density, BMI, and age at diagnosis
(OR, 1.84; 95% CI, 1.38 to 2.44) and was present in both the lowest
and highest quartile of mammographic density (Table 4). The effect
size associated with BMI was essentially unchanged after adjustments
for mammographic density, age, and HRT use. The effect was still
observed in the top quartile of mammographic density but was not
present in the lowest mammographic density quartile (Table 4). In-
cluding women without images in the analysis did not change esti-
mates, except that the effect of high age at menarche reached statistical
significance (OR, 1.22; 95% CI, 1.02 to 1.46). In sensitivity analysis of
survivor bias, the estimate for family history increased, whereas esti-
mates for HRT weakened (Appendix Table A2, online only).
DISCUSSION
In this study, we appraised clinicopathologic and risk factor differ-
ences between screen-detected breast cancers and interval breast can-
cers and the implications of mammographic density on obscuring
tumors that should have been detected at screening. Interval breast
cancers in nondense breasts were associated with aggressive tumor
characteristics compared with screen-detected breast cancers in non-
dense breasts, whereas interval breast cancers in dense breasts were
phenotypically more similar to dense screen-detected breast cancers.
Current HRT use, BMI, and family history were risk factors associated
with interval breast cancer.
The distribution of tumor characteristics between interval
breast cancers and screen-detected breast cancers overall was in full
agreement with the literature, with interval breast cancers being
larger at diagnosis and of higher grade, displaying more lymph
node involvement,1-6 and more often being ER/PR negative,2-4,6
HER2 positive,8 or triple negative.2,9 Interval breast cancers were
not significantly different in phenotype whether they had been
diagnosed 1 or 2 years after last screen. Instead, we found the
interval breast cancer phenotype to differ by mammographic den-
sity, with nondense interval breast cancers having a significantly
worse phenotype than dense interval breast cancers, compared
with screen-detected breast cancers. In support of this, Domingo et
al19 performed a retrospective review of interval breast cancers,
dividing them into true or missed, and reported true interval
cancers to be associated with a worse phenotype, with true interval
breast cancers also exhibiting weaker associations with mammo-
graphic density than missed interval breast cancers. Moreover, in
previous work from our group, we found survival of patients with
interval breast cancers to be poorer only in patients with nondense
breasts, after adjusting for tumor size at diagnosis.14 Together,
these results suggest that interval breast cancers in nondense
breasts are enriched for aggressive, true interval cancers.
We observed an increased risk of interval breast cancer among
women with a mother or sister with breast cancer. In concordance
with this, we found a two-fold increase in odds for interval breast
cancer among BRCA mutation carriers, although the patient numbers
were too low for these results to be conclusive. However, previous
studies of BRCA mutations have found a lowered sensitivity of the
mammography screening test for carriers,20-22 in line with our results.
Previous literature on family history and interval breast cancer reports
conflicting results, using varying definitions of family history and low
patient numbers (ranging from 47 to 375 patients with interval
cancer.2,3,7,8,10-13 We found that there is a small effect of family history
on the risk of interval cancer, but results will need to be confirmed in
other, larger studies.
Overweight women were more likely to have screen-detected
breast cancers, a finding that persisted after adjusting for age, HRT,
and mammographic density. BMI has been reported to be positively
associated with high-proliferating tumors23 but negatively associated
with percent mammographic density.24 Together, this makes the BMI
associations with interval detection difficult to interpret in a logistic
regression setting without distinguishing true from false interval
breast cancers, because an effect of BMI on growth rate is likely hidden
Table 4. Multivariable Analysis of Breast Cancer Risk Factors Showing ORs With Corresponding 95% CIs for Interval Cancers Relative to
Screen-Detected Cancers
Exposure
All Interval Cancers v
Screen-Detected Cancers
Low Mammographic




Density ( 40.9%): Interval
Cancers v Screen-Detected
Cancers
OR 95% CI OR 95% CI OR 95% CI
Hormone replacement therapy use
Never 1.00 1.00 1.00
Past 1.21 0.95 to 1.54 2.03 1.22 to 3.38 1.35 0.84 to 2.17
Current 1.84 1.38 to 2.44 2.42 1.67 to 5.04 2.47 1.49 to 4.08
Body mass index, kg/m2
 20 1.00 1.00 1.00
20-25 0.77 0.46 to 1.27 1.12 0.22 to 5.60 0.72 0.29 to 1.78
 25 0.49 0.29 to 0.82 1.08 0.22 to 5.35 0.38 0.15 to 0.97
Family history (mother or sister)†
No 1.00 1.00 1.00
Yes 1.32 1.02 to 1.70 1.66 0.96 to 2.87 1.28 0.77 to 2.11
Abbreviation: OR, odds ratio.
Model: Interval cancer as outcome, and age, body mass index, hormone replacement therapy use, and percent mammographic density as covariates.
†Model: Interval cancer as outcome, and family history, age, and percent mammographic density as covariates. Family history is defined as having a mother and/or
sister(s) with breast cancer.
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by an opposite effect through the negative association with mammo-
graphic density. Notably, the negative association with BMI was not
seen among the breasts with low density where the least favorable
interval cancer phenotype was present.
We confirmed a higher risk of interval breast cancer, relative to
screen-detected breast cancer, among current users of HRT, which has
been previously shown in the literature.1-3,7,10,25 The association was
attenuated, but not removed, after adjustments for age, mammo-
graphic density, and BMI and was present also in nondense breasts,
indicating an effect beyond mere masking. During our study period,
HRT users were advised to attend sporadic screening at private mam-
mography clinics outside of the screening program, creating surveil-
lance bias for this group, which may in part explain this phenomenon.
This study has limitations that must be acknowledged. A propor-
tion of interval breast cancers are missed screen-detected breast can-
cers, partly a result of high mammographic density masking the tumor
from detection.19 Thus, we performed an analysis stratified by the
highest and lowest quartile of density to obtain separate risk estimates.
For the Stockholm Screening program, an estimated 22% of cancers
were missed at screening.26 BRCA status may have been misclassified if
women not tested were in fact carriers, which could underestimate any
true effect. For family history, we did not have information on daugh-
ters with breast cancer. This could attenuate any true effect of family
history. Another limitation is that risk factor analysis may have been
influenced by survivor bias because the questionnaire data were avail-
able for women still alive in 2009. If so, our results from the risk factors
could underestimate any true effects relating to aggressive cancers. In
sensitivity analysis restricting our risk factor analysis to patients diag-
nosed in 2004 or later, point estimates did not change overall. How-
ever, among the patients with nondense breasts, we saw a decrease in
the effect size of current HRT use and an increase in the point estimate
for family history (Appendix Table A2).
Our study has several strengths given the sample size and quality
and quantity of data available. For main analysis of tumor character-
istics, we have population-based data, giving us one of the largest
interval breast cancer versus screen-detected breast cancer breast can-
cer cohorts hitherto studied. In addition, we have the combination of
tumor characteristics, detailed questionnaire data, and area-based
mammographic density measurements available for 1,957 women,
enabling us to address the impact of mammographic density on prog-
nostic factors and risk factors of interval cancers in one of the largest
interval breast cancer studies to date.
In conclusion, interval breast cancers and screen-detected breast
cancers show disparate clinicopathologic features and are associated
with several breast cancer risk factors differently. Interval breast can-
cers among women with low mammographic density have the most
aggressive phenotype, indicating enrichment of true interval breast
cancers within this group. In the future, screening programs should
shift from solely age-based to individual risk–based programs. Diag-
nostic modality and screening intervals for individual women could
be decided based on risk factors such as mammographic density and
genetic background.
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GLOSSARY TERMS
HER2/neu (human epidermal growth factor recep-
tor 2): also called ErbB2. HER2/neu belongs to the epidermal
growth factor receptor (EGFR) family and is overexpressed in
several solid tumors. Like EGFR, it is a tyrosine kinase receptor
whose activation leads to proliferative signals within the cells. On
activation, the human epidermal growth factor family of recep-
tors are known to form homodimers and heterodimers, each
with a distinct signaling activity. Because HER2 is the preferred
dimerization partner when heterodimers are formed, it is impor-
tant for signaling through ligands specific for any members of the
family. It is typically overexpressed in several epithelial tumors.
logistic regression analysis: a multivariable regression
model in which the log of the odds of a time-fixed outcome event
(eg, 30-day mortality) or other binary outcome is related to a linear
equation.
population-based study: a study in which the patients are drawn
from a defined population in a manner that is representative of the
source population studied. Such a design can avoid bias arising from the
selective factors that guide affected individuals to a particular medical
facility, allowing for greater generalizability of the findings.
triple-negative phenotype: breast tumors that are negative for
progesterone and estrogen and that underexpress HER2.
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Appendix
Table A1. Tumor Characteristics for Interval Cancers and Screen-Detected Cancers in the Full Cohort and Women With Questionnaire Data
Tumor Characteristic











No. of Patients % No. of Patients % OR 95% CI No. of Patients % No. of Patients % OR 95% CI
Tumor size, mm
 20 2,061 74 654 55 1.00 Ref 1,269 75 438 57 1.00 Ref
20-40 629 22 439 37 2.20 1.89 to 2.57 370 22 272 36 2.13 1.76 to 2.58
 40 114 4 93 8 2.57 1.93 to 3.43 58 3 53 7 2.65 1.80 to 3.90
Lymph nodes
Negative 2,658 94 1,061 86 1.00 Ref 1,616 94 686 88 1.00 Ref
Positive 181 6 172 14 2.38 1.91 to 2.97 98 6 97 12 2.33 1.74 to 3.13
Grade
1 504 27 106 15 1.00 Ref 300 26 73 15 1.00 Ref
2 976 53 346 48 1.69 1.32 to 2.15 624 55 241 50 1.59 1.18 to 2.13
3 358 20 266 37 3.53 2.72 to 4.59 213 19 166 35 3.20 2.31 to 4.44
Estrogen receptor
Positive 2,144 91 727 78 1.00 Ref 1,326 92 496 80 1.00 Ref
Negative 210 9 204 22 2.87 2.32 to 3.54 121 8 124 20 2.74 2.09 to 3.60
Progesterone receptor
Positive 1,714 75 530 59 1.00 Ref 1,063 75 361 60 1.00 Ref
Negative 586 25 375 41 2.07 1.76 to 2.43 357 25 291 40 1.99 1.63 to 2.44
HER2
Positive 59 9 51 18 2.35 1.57 to 3.52 46 11 40 19 1.97 1.23 to 3.16
Negative 633 91 233 82 1.00 Ref 390 89 155 81 1.00 Ref
Triple negative
Yes 30 4 45 16 4.22 2.60 to 6.86 21 5 28 15 3.45 1.90 to 6.26
No 653 96 232 84 1.00 Ref 409 95 148 85 1.00 Ref
Histology
Ductal 1,941 70 184 69 1.00 Ref 1,180 71 112 71 1.00 Ref
Lobular 297 13 837 15 1.16 0.96 to 1.41 231 14 545 15 1.05 0.82 to 1.34
Abbreviations: HER2, human epidermal growth factor receptor 2; Ref, reference.
HER2 recorded from 2007. Grade recorded from 2004.
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Table A2. Sensitivity Analysis of Survivor Bias: Multivariable Logistic Regression of Interval Breast Cancers Versus Screen-Detected Breast Cancers Using Only









OR 95% CI OR 95% CI OR 95% CI
Hormone replacement therapy
Never 1.00 1.00 1.00
Past 1.13 0.84 to 1.52 1.58 0.84 to 2.99 1.66 0.92 to 3.01
Current 1.54 1.04 to 2.28 1.47 0.48 to 4.52 2.53 1.28 to 4.99
Body mass index, kg/m2
 20 1.00 1.00 1.00
20-25 0.76 0.40 to 1.45 0.61 0.11 to 3.47 0.48 0.16 to 1.42
 25 0.44 0.23 to 0.86 0.54 0.10 to 2.97 0.30 0.10 to 0.93
Family history (mother or sister)†
No 1.00 1.00 1.00
Yes 1.30 0.94 to 1.79 2.08 1.06 to 4.10 1.37 0.73 to 2.56
Abbreviation: OR, odds ratio.
Model: Age, body mass index, hormone replacement therapy use, and percent mammographic density as covariates.
†Model: Family history, age, and percent mammographic density as covariates.
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